substances that contribute to impaired microvascular perfusion.
obstruction of the coronary microcirculation after microembolization of debris and release of soluble vasoconstrictor substances from the ruptured atherosclerotic plaque contribute to the loss of viable myocardium. Protection devices are used to prevent debris and vasoconstrictor substances from being washed into the coronary microcirculation during PCI, but apart from the reduction of thrombus burden by thromboaspiration in acute myocardial infarction, their clinical benefit has been modest at best. 11 Therefore, the prevention of coronary microcirculatory impairment by vasodilator drugs is still an attractive target.
We have now taken advantage of the use of an aspiration device during stenting of saphenous vein aortocoronary bypass grafts and analyzed the aspirate plasma, which induces profound vasoconstriction in a rat mesenteric vasomotor bioassay, for its soluble vasoconstrictor, thrombogenic, and inflammatory constituents. [12] [13] [14] Of note, we have also studied the potential pharmacological antagonism of the observed vasoconstriction with the aim of developing a more rational treatment of the no-reflow phenomenon.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Patients
Twenty-two symptomatic patients (20 men, 2 women; age, 68Ϯ4 years) with a significant diameter stenosis (Ͼ75%) in a saphenous vein aortocoronary bypass graft were studied. All patients were on aspirin (100 mg/d) and received 10 000 IU of heparin intravenously. Coronary angiography was performed via the femoral approach. Quantification of stenosis severity was performed with the use of off-line caliper measurements (QCA-MEDIS, Leiden, The Netherlands). Thrombolysis in myocardial infarction (TIMI) flow was determined before and after each intervention. 15 Saphenous vein graft age, target vessels, laboratory blood analysis, comorbidities, and current medications are presented in Online Table I . The investigation conforms to the principles outlined in the Declaration of Helsinki. The study protocol was approved by the local Institutional Review Board of the University of Essen School of Medicine (GZ.: 05-2807). Full informed consent was obtained from all patients before participating in the study.
Interventional Procedure
The implantation of balloon-expandable bare-metal stents (Bx Sonic, Cordis Corp, Miami, FL; Genius Magic, Eurocor GmbH, Bonn, Germany; Lekton, Biotronic SE & CoKG, Berlin, Germany) was performed using maximum balloon pressures of Ͼ14 atm and a balloon-to-vessel diameter ratio of 1:1. To prevent microembolization, a distal balloon occlusion flushing/extraction device (TriAktiv SVG/3.5-FX-catheter; Kensey Nash, Exton, PA) was used. The balloon guide wire was placed distal to the lesion and inflated at 2 atm with carbon dioxide. After stent implantation the interventional catheter was removed, and the LFX catheter was loaded on the guide wire. During slow withdrawal of this catheter, the stented area was flushed with saline and the blood-saline mixture was retrieved. Then, the balloon was deflated.
Blood Samples
Arterial blood was taken via the flushing/extraction catheter (10 mL into potassium EDTA S-Monovette, SARSTEDT AG & Co, Nümbrecht, Germany) distal to the lesion before the intervention. Aspirate (20 mL) was obtained during the intervention, diluted with saline to an approximately blood/saline-ratio Ϸ1:2 vol/vol and filtered ex vivo through a 40-m mesh filter. The aspirate dilution was corrected for by reference to the hematocrit. In each instance, visible particulate debris was retained on the filter. The filtered aspirate and the arterial blood were immediately centrifuged (600g, 10 minutes, 4°C), and the plasma was removed, quickly frozen in liquid nitrogen, and stored at Ϫ80°C until further use. Troponin I was determined in venous plasma before the intervention and at 6, 12, 24, 36, and 48 hours after the intervention using a specific 2-side immunoassay (Dimension Flex, Dade Behring GmbH, Marburg, Germany). The detection range of troponin I was 0.04 to 40 ng/mL; the upper limit of normal was 0.1 ng/mL. Plasma aliquots from healthy volunteers were also frozen in liquid nitrogen and stored at Ϫ80°C.
Plasma Concentration of Vasoconstrictors, Tissue Factor, and Tumor Necrosis Factor ␣
The plasma concentration of several vasoconstrictors in coronary arterial blood and aspirate was measured: epinephrine, norepinephrine, and serotonin were determined using high-performance liquid chromatography and electrochemical detection (Chromsystems, München, Germany). Endothelin and thromboxane (Tx)B 2 were measured using ACE immunoassays (Cayman Chemical Company, Ann Arbor, MI). Tissue factor was measured using IMUBIND Tissue Factor Elisa Kit (American Diagnostica Inc, Stamford, CT). Tumor necrosis factor (TNF)␣ was determined using a sandwich enzyme immunoassay (Quantikine Human TNF-␣/TNFSF1A, R&D Systems, Abingdon, UK). For details, see the Online Data Supplement.
Vasomotor Bioassay
Human coronary arteries and rat mesenteric arteries are characterized by a comparable receptor arrangement for adenosine, epinephrine, norepinephrine, serotonin, and TxA 2 . 13,16 -19 Therefore, we used rat mesenteric arteries to characterize the vasomotion in response to coronary arterial and aspirate plasma and to subsequent vasodilators.
Male Lewis rats were euthanized after enflurane-inhalation anesthesia by rapidly removing the heart, in accordance with the German laws for animal welfare and approved by the local review committee. The mesenteric arteries were dissected and perfused with saline at 60 mm Hg; their diameter was 152Ϯ15 m on light microscopic examination (nϭ16). Segments of 2-mm length were mounted with intact endothelium (ϩE) and after mechanical removal of the endothelium (ϪE) into the Mulvany myograph (Danish Myo Technology, Aarhus, Denmark). Maximal vasoconstriction was defined by the response to potassium chloride (KCl; 1.2ϫ10 Ϫ1 mol/L). Subsequently, arteries were washed and rechallenged with norepinephrine (10 Ϫ5 mol/L) and carbachol (10 Ϫ4 mol/L) to verify a strong agonist response and endothelial functionality, as previously described. 13 For details, see the Online Data Supplement. 
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Experimental Protocols
Rat mesenteric arteries (ϩE and ϪE) were incubated with coronary arterial and aspirate plasma. Coronary arterial and aspirate plasma were diluted to a final ratio of 1:10 vol/vol each. The contribution of serotonin and/or TxA 2 to the vasoconstriction by aspirate plasma was determined by use of selective blockade of serotonin receptors by ketanserin (5-hydroxytryptamine [5-HT] 2A/2C receptor blocker with ␣ 1 -adrenoceptor blocker effects) and pindolol (␤-adrenoceptor blocker with 5-HT 1A/1B receptor blocker effects) and of TxA 2 receptors by ICI 185,282 (TxA 2 receptor blocker) and their combination (each 10 Ϫ9 to 10 Ϫ4 mol/L). 20, 21 To characterize the concentration-dependent actions of serotonin and thromboxane, arteries were exposed to plasma of healthy volunteers and vasoconstriction was then determined after addition of serotonin and U-46619 (the metabolically stable analog of TxA 2 22 ) (each 10 Ϫ10 to 10 Ϫ5 mol/L). In a subset of experiments, we determined the impact of TNF␣ on the vasoconstriction by serotonin and U-46619. Arteries were exposed to plasma of healthy controls supplemented with a combination of serotonin (3.5 pg/mL) and U-46619 (50 pg/mL) with and without TNF␣ (50 pg/mL).
The dilator responses of mesenteric arteries to adenosine, nitroprusside, and verapamil were determined after constriction by aspirate plasma. When a plateau of constriction had been reached, dilation was induced by adding cumulatively increasing concentrations of adenosine, nitroprusside, or verapamil (each 10 Ϫ9 to 10 Ϫ4 mol/L). Dilator responses were expressed as percentage of the maximum vasoconstriction induced by the coronary aspirate.
Statistical Analysis
All data are given as the meansϮSEM. Troponin I data and the release of substances into the coronary aspirate were evaluated with a paired t test. Statistical comparisons of concentration-response curves were made by 2-way ANOVA followed by Bonferroni post hoc tests to assess differences between treatment groups (SigmaStat 2.03, SPSS Inc, Chicago, IL). In addition, concentration-response curves were analyzed in terms of half-maximal effective concentration (EC 50 ) after least-square sigmoidal curve fitting of individual curves using Origin 7G SR2 (Northampton, MA). Probability values of less than 0.05 were considered statistically significant.
Results
In all patients, we retrieved an aspirate of 77Ϯ4 mL (after correction for dilution by the hematocrit). In each instance, particulate debris was retained on the ex vivo filter. TIMI flow was I in 3 and II in 19 patients before the intervention, and was II in 3 and III in 19 patients after the intervention. Troponin I was 0.049Ϯ0.02 ng/mL before and 0.16Ϯ0.02 ng/mL (PϽ0.05) at its maximum after the intervention. Troponin I exceeded the proposed cutoff level of 0.15 ng/mL 23 
Release of Vasoconstrictors, Tissue Factor, and TNF␣ Into the Aspirate
The concentrations of endothelin, epinephrine, norepinephrine, and tissue factor were not different before and after stent implantation ( Table 1) . Coronary aspirate plasma levels of serotonin, TxB 2 , and TNF␣ increased by 1.9Ϯ0.2 mol/L, 25.6Ϯ3.1 pg/mL, and 19.7Ϯ6.1 pg/mL, respectively, during stent implantation (Table 1) .
Vasoconstriction by Coronary Arterial and Aspirate Plasma
Coronary arterial plasma withdrawn distal to the lesion before stent implantation induced a vasoconstriction which amounted to 21Ϯ5% (ϩE) and 34Ϯ8% (ϪE) of that by KCl (100%). The vasoconstriction of aspirate plasma, however, was 95Ϯ8% (ϩE) and 101Ϯ9% (ϪE) of that by KCl (100%). The extent of vasoconstriction was independent from the integrity of the endothelium (Figure 1 ). Arteries constricted immediately after the exposure to aspirate plasma, and a stable maximum was reached within 2 to 4 minutes. Representative original registrations of constriction in response to coronary arterial and aspirate plasma are presented in Figure  1A and 1B.
Potentiation of Vasoconstriction by TNF␣
The rat mesenteric arteries ex vivo constricted in response to plasma supplemented with serotonin and the TxA 2 analog U-46619 ( Figure 2 ; Online Figure III); this vasoconstriction was weaker in vessels with (ϩE, 85Ϯ4%) than without (ϪE, 124Ϯ5%) endothelium. The vasoconstriction in vessels ϩE was potentiated by TNF␣ (111Ϯ8%) but not that in vessels ϪE (118Ϯ3%), indicating that TNF␣ per se does not induce vasoconstriction ( Figure 2 ).
Antagonism of Vasoconstriction by Selective Blockade of Serotonin and Thromboxane Receptors
In aspirate plasma-constricted arteries, selective serotonin receptor blockade dose-dependently attenuated vasoconstric-tion in the presence and absence of endothelium and abolished vasoconstriction at the highest concentration. In contrast, selective thromboxane receptor blockade only somewhat attenuated the aspirate plasma-induced vasoconstriction. Combined blockade of serotonin and thromboxane receptors was somewhat more potent than serotonin receptor blockade alone ( Figure 3 and Table 2 ). Likewise, exogenous serotonin at the concentration observed in the retrieved aspirate plasma induced maximum vasoconstriction (118% ϩE and 141% ϪE of KCl-induced vasoconstriction); the TxA 2 analog U-46619 at the concentration of TxB 2 observed in aspirate plasma induced no vasoconstriction (Online Figure III ).
Antagonism of Vasoconstriction by Adenosine, Nitroprusside, and Verapamil
In aspirate plasma-constricted arteries, both nitroprusside and verapamil concentration-dependently and endotheliumindependently attenuated vasoconstriction and virtually abolished it at their highest concentrations. In contrast, the effect of adenosine was endothelium-dependent and weaker than that for nitroprusside and verapamil (Figures 4 and 5 and Table 3 ). Representative original registrations of constriction in response to aspirate plasma and the following attenuation of the vasoconstriction by adenosine, nitroprusside, and verapamil are presented in Online Figure IV.
Discussion
The present study confirms prior studies by others 24 -26 and ourselves 13 on the release of serotonin from stented coronary vessels, but extends those studies and provides significant novel information:
• We measured biochemically the release of a number of mediators; excluded a role for catecholamines, endothelin, and tissue factor in the observed vasoconstriction; defined the quantitative contribution of serotonin and thromboxane (which only potentiates the serotonin response) by selective pharmacological blockade; and demonstrated a facilitatory role for TNF␣ through impairment of endothelial function. • Of note, and of clinical relevance, we report the largely different potency of prototype pharmacological vasodilators, notably the inability of adenosine, to attenuate the coronary aspirate-induced vasoconstriction.
Release of Vasoconstrictor, Thrombogenic, and Inflammatory Factors During Plaque Rupture
In the present study, we have taken advantage of the clinical situation of patients undergoing interventional atherosclerotic plaque rupture. During stenting of stenotic saphenous vein aortocoronary bypass grafts, we retrieved the aspirate from a protection device and identified the release of vasoconstrictor (serotonin, thromboxane), thrombogenic (thromboxane), and inflammatory (TNF␣) substances. The atherosclerotic plaque composition of saphenous vein grafts differs from that of native vessels, [27] [28] [29] and saphenous vein grafts are particularly vulnerable to plaque rupture. 30 Also, we do not know to what extent the traumatic PCI-induced plaque rupture mirrors the spontaneous plaque rupture during acute myocardial infarction. Still, we identified the release of substances that impair myocardial perfusion, and the no-reflow phenomenon is a characteristic complication of both PCI (particularly of saphenous vein grafts) and acute myocardial infarction.
Vasoconstrictor Potential of Coronary Aspirate
Baseline concentrations of arterial plasma catecholamines were elevated, probably reflecting the stress situation of PCI. However, there was no net release of catecholamines into the aspirate during PCI. Also, there was no net release of endothelin and tissue factor during the elective PCI in our study. In contrast, net endothelin release into the aspirate has been reported in primary PCI after acute myocardial infarction. 31, 32 Also, net release of tissue factor into the aspirate has been reported during acute coronary syndromes. 33, 34 It is unclear to what extent the different underlying atherosclerotic substrates (saphenous vein graft vs native vessel), the nature of plaque rupture (traumatic vs spontaneous), or the interaction with thrombotic processes in the acute coronary syndromes contributes to such differences in endothelin and tissue factor release. We confirmed the net release of serotonin and thromboxane into the aspirate as in our prior study, where we demonstrated that the aspirate-induced vasoconstriction is eliminated by combined pharmacological antagonism of serotonin and thromboxane. 13 Serotonin and thromboxane have also previously been demonstrated to be released into the coronary blood during PCI and to contribute to no-reflow. 24 -26 In the present study, we extended our prior observation and determined the separate contribution of serotonin and thromboxane, respectively, to the vasoconstriction by the aspirate. Serotonin was largely responsible for the observed vasoconstriction, and thromboxane only contributed by potentiating the serotonininduced response, as evidenced by the slight leftward shift of the concentration-response curve with combined serotonin and thromboxane blockade as compared to serotonin blockade alone.
Somewhat surprisingly, there was net thromboxane release, although all patients received 100 mg of aspirin daily. However, thromboxane is not only synthesized in platelets, but also in monocytes/macrophages and in vascular cells via cyclooxygenase (COX)-2. Although platelets are persistently inactivated by aspirin, the nucleated cells can rapidly recover from the aspirin-dependent irreversible inhibition of COX-2 activity through de novo synthesis of COX-2 in response to inflammatory and mitogenic stimuli, especially in symptomatic atherosclerotic plaques. [35] [36] [37] Also, we cannot exclude an insufficient suppression of platelet TxA 2 production in some of our patients. 38 We also confirmed the release of the TNF␣ into the aspirate. 14 TNF␣ is a proinflammatory cytokine that impairs endothelium-dependent vasodilation. 39 Such impairment of endothelium-dependent vasodilation is of particular importance in the coronary circulation during myocardial ischemia/ reperfusion. 40 -42 In the present study, we demonstrated that TNF␣ potentiates the vasoconstriction induced by the combination of serotonin and thromboxane. Because the potentiation of serotonin/thromboxane-induced vasoconstriction by TNF␣ was only seen in the presence of intact endothelium, such apparent potentiation most likely results from the elimination of the endothelium-dependent dilation by serotonin after 5HT 1B receptor stimulation. 43
Pharmacological Attenuation of Vasoconstriction
European Society of Cardiology guidelines for acute myocardial infarction 44 and PCI 45 recommend the use of vasodilators to treat no-reflow, notably that of adenosine, nitroprusside, and verapamil. However, in the present study, adenosine was not as potent to attenuate the aspirate-induced vasoconstriction as nitroprusside or verapamil. The failure of adenosine to fully antagonize the aspirate-induced vasoconstriction in our study is not related to species, organ of origin, or size of our bioassay vessels, because human coronary small arteries/ arterioles of the same diameter range (140 m) have quantitatively similar dilator responses to adenosine as our rat mesenteric bioassay vessels. 19 Adenosine often fails to induce maximal coronary dilation also in patients with coronary artery disease. 46 Very recently, intracoronary high-dose adenosine also failed to attenuate microvascular obstruction in patients with acute myocardial infarction undergoing primary PCI. 47 In contrast to adenosine, both nitroprusside and verapamil dose-dependently and eventually fully attenuated the aspirate-induced vasoconstriction, and the dilator action was not endothelium-dependent. The functional antagonism of the aspirate-induced vasoconstriction by nitroprusside and verapamil was as potent as the competitive antagonism for both serotonin at 5HT 2A/2C and 5HT 1A/1B receptors and TxA 2 at thromboxane-prostanoid receptors in our prior study. 13 Both nitroprusside 48, 49 and verapamil 8 have been clinically used to potentially reverse no-reflow. Intracoronary nitroprusside has the advantage of having no hemodynamic side-effects. 49, 50 In contrast, intracoronary verapamil can cause bradyarrhythmias, 51, 52 but it may also attenuate stunning 53 and contribute to a reduction of infarct size. 54 Also, the half-life of verapamil is longer, and it does not require continuous intracoronary infusion.
In conclusion, we have identified the release of serotonin, thromboxane, and TNF␣ during stenting of saphenous vein aortocoronary bypass grafts. The vasoconstrictor activity of serotonin and thromboxane is fully attenuated by nitroprusside or verapamil but not by adenosine. The action of nitroprusside and verapamil is not dependent on functional endothelium and therefore expected to functionally antagonize microvascular constriction also in patients with endothelial dysfunction.
Study Limitations
Our study is limited to a small number of patients undergoing elective PCI of saphenous vein bypass grafts, and further studies on a larger scale and with a focus on the coronary microcirculation are needed. Also, our study used rat mesenteric microvessels as bioassay. Although rat mesenteric microvessels share essential properties with human coronary microvessels, 19 further studies with an isolated heart bioassay system are warranted to study the impact of coronary aspirate on the coronary microcirculation and on cardiac contraction.
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Novelty and Significance
What Is Known?
• Particulate debris from ruptured coronary atherosclerotic plaques embolizes into the microcirculation. • Release of vasoconstrictor, thrombogenic, and inflammatory substances also contributes to coronary microvascular flow impairment.
What New Information Does This Article Contribute?
• Stent implantation in patients with saphenous vein graft stenosis causes release of serotonin, thromboxane and tumor necrosis factor (TNF)␣ into the coronary arterial blood. • Serotonin causes vasoconstriction in a rat mesenteric bioassay, which is potentiated by thromboxane and TNF␣. • Nitroprusside and verapamil, but not adenosine, effectively antagonize such vasoconstriction.
The spontaneous or periinterventional rupture of an atherosclerotic plaque in an epicardial coronary artery does not always result in complete thrombotic occlusion and impending myocardial infarction, but often some residual blood flow is retained and the atherosclerotic debris, together with superimposed thrombotic material, is dislodged into the coronary microcirculation, where it causes microinfarcts, along with an inflammatory reaction. Not only particulate debris but also soluble vasoconstrictor, thrombogenic, and inflammatory mediators are released during plaque rupture and contribute to microcirculatory impairment. The present study takes advantage of stent implantation in patients with severe saphenous vein bypass graft stenoses and analyzes the coronary aspirate retrieved with a protection device during stent implantation for its vasoconstrictor, thrombogenic, and inflammatory mediators. Serotonin is quantified as the main coronary vasoconstrictor, and its constrictor action is potentiated by thromboxane and TNF␣ in a rat mesenteric bioassay. Nitroprusside and verapamil, but not adenosine, can effectively antagonize the observed vasoconstriction. These data suggest use of nitroprusside or verapamil rather than adenosine to prevent/attenuate a no-reflow phenomenon.
